Dermira gets positive results in clinical trial of new drug lebrikizumab2b phase 2b

today, Dermira(http://announced that the company developed a new drug(http://in
the treatment of severe isotrophic dermatitis, whichin the http:// of the 2b dose
increment severity trial(http://all three dosesreached the main endpoint of the trial, significantly improving the eczema area and severity index (EASI) in patients compared to placeboAbout Lebrikizumab
Lebrikizumab is an innovative humanized anti-IL-13 monoclonal antibodyIt binds to IL-13 with high affinity and high specificity, thus preventing the formation of the IL-13R alpha1/IL-4R alpha complex and inhibiting the signaling pathway sway of this receptor complexIL-13 is considered to be a key factor in mediated atheoritis, which promotes type 2 inflammatory response, driving the pathophysiology of asexual dermatitis in many waysIn this randomized double-blind, placebo-controlled Phase 2b clinical trial, 280 patients with moderate and severe asexual dermatitis over the age of 18 were divided into four groups and treated with different doses of lebrikizumab and placebo results showed that after 16 weeks of treatment, lebrikizumab statistics significantly improved the symptoms of patients assessed by EASI Compared to baseline, the EASI score improved by 62.3% (125 mg/week, p .0165), 69.2% (250 mg/four weeks, p.0.0022), and 72.1% (250 mg/two weeks, p.0005), and eASI improved by 41.1% in the control group At the same time, the 250 mg/4 weeks and 250 mg/two-week treatment groups reached multiple secondary endpoints 　　About acursion dermatitis one of the most common and severe types of eczema, which occurs in early childhood and can continue into adulthood This is a chronic inflammatory disease, characterized by a rash on the surface of the skin, which can cover most of the body, causing redness, dry cracking and persistent severe itching